Purchase disclosed
Declan Doogan
Director
Common Stock
- Reported value
- $101.76K
- Reported price
- $1.92 / share
Loading data…Scanning SEC filings…Checking Congress reports…Following the signal…
TENAX THERAPEUTICS, INC.
Last 30 daysInsiders bought $1.74M · 4 buyers, led by ADAR1 Capital Management (10% owner) with $1.6M. No qualifying insider sales.
Showing the first 6 of 17 trades on this page.
Director
Common Stock
CEO
Common Stock
CEO
Common Stock
Chief Financial Officer
Common Stock
10% owner
Common Stock
10% owner
Common Stock
10% owner
Common Stock
10% owner
Common Stock
10% owner
Common Stock
10% owner
Common Stock
10% owner
Common Stock
CEO
Common Stock
CEO
Common Stock
CEO
Stock Option (right to buy)
Derivative security · not the ordinary share price.
This row records an option exercise or conversion. The derivative transaction price is separate from the exercise price; it is not the stock's market price. Its row value is not shown as another stock purchase.
CEO
Stock Option (right to buy)
Derivative security · not the ordinary share price.
This row records an option exercise or conversion. The derivative transaction price is separate from the exercise price; it is not the stock's market price. Its row value is not shown as another stock purchase.
Chief Financial Officer
Common Stock
The filing reports a zero transaction price for this award. It does not mean the awarded securities have no market value.
Chief Financial Officer
Stock Option (right to buy)
Derivative security · not the ordinary share price.
The filing reports a zero transaction price for this award. It does not mean the awarded securities have no market value.
| Reporting insider | Security / transaction | Amount / price | Value | Traded / disclosed | Source |
|---|---|---|---|---|---|
| Director | Common StockPurchase | 53,000$1.92 / share | $101.76K | Sep 16Filed Sep 17 · 1d later | SEC filing |
| CEO | Common StockPurchase | 6,000$1.88 / share | $11.25K | Sep 11Filed Sep 15 · 4d later | SEC filing |
| CEO | Common StockPurchase | 4,850$1.82 / share | $8.84K | Sep 15Filed Sep 15 · 0d later | SEC filing |
| Chief Financial Officer | Common StockPurchase | 5,675$1.94 / share | $10.98K | Sep 11Filed Sep 15 · 4d later | SEC filing |
| +110% owner | Common StockPurchase | 900,000$1.78 / share | $1.6M | Sep 3Filed Sep 8 · 5d later | SEC filing |
| +110% owner | Common StockPurchase | 403,571$1.79 / share | $722.59K | Aug 31Filed Sep 2 · 2d later | SEC filing |
| +110% owner | Common StockPurchase | 179,058$1.80 / share | $321.57K | Sep 1Filed Sep 2 · 1d later | SEC filing |
| +110% owner | Common StockPurchase | 187,704$1.80 / share | $337.59K | Sep 2Filed Sep 2 · 0d later | SEC filing |
| +110% owner | Common StockPurchase | 202,124$1.78 / share | $359.54K | Aug 20Filed Aug 24 · 4d later | SEC filing |
| +110% owner | Common StockPurchase | 716,369$1.77 / share | $1.27M | Aug 21Filed Aug 24 · 3d later | SEC filing |
| +110% owner | Common StockPurchase | 107,374$1.75 / share | $188.36K | Aug 24Filed Aug 24 · 0d later | SEC filing |
| CEO | Common StockOption exercise or conversion | 219$3.55 / share | $777.23 | Jul 13Filed Jul 14 · 1d later | SEC filing |
| CEO | Common StockOption exercise or conversion | 8,500$5.94 / share | $50.49K | Jul 13Filed Jul 14 · 1d later | SEC filing |
| CEO | Stock Option (right to buy)Option exercise or conversion | Derivative units219$3.55 exercise / conversion price | Not a separate purchase | Jul 13Filed Jul 14 · 1d later | SEC filing |
| CEO | Stock Option (right to buy)Option exercise or conversion | Derivative units8,500$5.94 exercise / conversion price | Not a separate purchase | Jul 13Filed Jul 14 · 1d later | SEC filing |
| Chief Financial Officer | Common StockGrant or award | 10,000Award · no purchase price | Non-cash award | May 11Filed May 13 · 2d later | SEC filing |
| Chief Financial Officer | Stock Option (right to buy)Grant or award | Derivative units450,000Award · no purchase price | Non-cash award | May 11Filed May 13 · 2d later | SEC filing |
This reflects the filings imported so far, not a complete trading history.
$3,719,588 of common-equity purchase value after transaction-age decay across 180 days.
4 distinct reporting-owner group(s). Joint rows count once; identity is not proof of discretion.
Qualifying common-equity P acquisition; no disclosed plan, exercise or excluded purchase context detected.
Qualifying common-equity P acquisition; no disclosed plan, exercise or excluded purchase context detected.
3 buying groups inside 30 transaction-date days, public by the snapshot cutoff.
A reporting-owner group bought on at least two distinct dates within the cluster window.
At least one row increased reported same-security holdings by 10% or established a new reported position; indirect interests may overlap.
This score describes qualifying insider purchases at issuer level. Read the methodology
Open a transaction's SEC filing for the primary evidence. A code P may describe an open-market or private purchase; classification is not proof of intent.
Insider activity can have many explanations. Signal Strength is not a probability of profit or a recommendation to trade.